GLP-1 drug pipeline tracker

The next wave of weight-loss and metabolic drugs in development — and what their approval could mean for Bridge coverage.

Several next-generation GLP-1 and multi-receptor drugs are moving through clinical trials. As each one earns FDA approval, it becomes a candidate for Medicare Part D and Bridge coverage — potentially expanding options and, over time, increasing competition on price. Below we track the most-watched candidates. Phases and dates are estimates and change as trials report out.

Retatrutide

Phase 3

Eli Lilly

  • Mechanism: Triple agonist (GLP-1 + GIP + glucagon)
  • Expected approval: ~2026–2027
  • Bridge potential: High — early trials show some of the largest weight-loss results to date

Orforglipron

Phase 3

Eli Lilly

  • Mechanism: Oral (non-peptide) GLP-1 receptor agonist
  • Expected approval: ~2026
  • Bridge potential: High — a daily pill could simplify access and pharmacy logistics

CagriSema

Phase 3

Novo Nordisk

  • Mechanism: Cagrilintide (amylin) + semaglutide combination
  • Expected approval: ~2026–2027
  • Bridge potential: High — positioned as a next step beyond Wegovy

Survodutide

Phase 2/3

Boehringer Ingelheim / Zealand

  • Mechanism: GLP-1 + glucagon dual agonist
  • Expected approval: ~2027+
  • Bridge potential: Moderate — also studied for liver disease (MASH)

Pemvidutide

Phase 2

Altimmune

  • Mechanism: GLP-1 + glucagon dual agonist
  • Expected approval: ~2027–2028
  • Bridge potential: Early — watch for Phase 3 results

Oral semaglutide (Wegovy pill)

Filed / Phase 3

Novo Nordisk

  • Mechanism: Oral semaglutide at weight-management dose
  • Expected approval: Near-term
  • Bridge potential: High — extends an already-covered molecule to pill form

Phase legend: trials progress Phase 1 → 2 → 3 → FDA review. Sources: FDA.gov drug development & approvals; company clinical-trial disclosures. Estimates only and subject to change.

What approval means for Bridge coverage

FDA approval is the first gate. After that, a drug must be added to a Part D plan's formulary and meet the Bridge program's qualifying-condition rules before it's covered for you. New approvals can take months to a year-plus to appear on formularies, and prior authorization usually applies. We'll update this tracker as candidates advance.

See what's covered today → Check my eligibility

Disclaimer: GLP1Bridge.com is an independent informational resource and is not affiliated with Medicare, CMS, the FDA, or any drug manufacturer. Pipeline phases and approval estimates change frequently and are not guarantees. Not medical advice. Sources: FDA.gov, CMS.gov.